Education
About Us
Working with TipRanks
Follow Us
NewAmsterdam Pharma Company (NAMS)
NASDAQ:NAMS
RESEARCH TOOLSreports
Total Valuation
NewAmsterdam Pharma Company has a market cap or net worth of $2.14B. The enterprise value is $1.29B.
Market Cap$2.14B
Enterprise Value$1.29B
Share Statistics
NewAmsterdam Pharma Company has 112,270,676 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding112,270,676
Owned by Insiders16.67%
Owned by Institutions2.64%
Financial Efficiency
NewAmsterdam Pharma Company’s return on equity (ROE) is -0.32 and return on invested capital (ROIC) is -23.26%.
Return on Equity (ROE)-0.32
Return on Assets (ROA)-0.28
Return on Invested Capital (ROIC)-23.26%
Return on Capital Employed (ROCE)-0.23
Revenue Per Employee670.04K
Profits Per Employee-3.55M
Employee Count68
Asset Turnover0.05
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of NewAmsterdam Pharma Company is -10.04. NewAmsterdam Pharma Company’s PEG ratio is 0.34.
PE Ratio-10.04
PS Ratio0.00
PB Ratio2.35
Price to Fair Value3.20
Price to FCF-13.58
Price to Operating Cash Flow-11.80
PEG Ratio0.34
Income Statement
In the last 12 months, NewAmsterdam Pharma Company had revenue of 45.56M and earned -241.60M in profits. Earnings per share was -2.56.
Revenue45.56M
Gross Profit45.45M
Operating Income-176.29M
Pretax Income-241.60M
Net Income-241.60M
EBITDA-241.49M
Earnings Per Share (EPS)-2.56
Cash Flow
In the last 12 months, operating cash flow was -151.09M and capital expenditures -78.00K, giving a free cash flow of -101.23M billion.
Operating Cash Flow-151.09M
Free Cash Flow-101.23M
Free Cash Flow per Share-0.90
Dividends & Yields
NewAmsterdam Pharma Company pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.77
52-Week Price Change-2.31%
50-Day Moving Average19.44
200-Day Moving Average19.90
Relative Strength Index (RSI)52.71
Average Volume (3m)796.17K
Important Dates
NewAmsterdam Pharma Company upcoming earnings date is Aug 12, 2025, TBA Not Confirmed.
Last Earnings DateMay 8, 2025
Next Earnings DateAug 12, 2025
Ex-Dividend Date―
Financial Position
NewAmsterdam Pharma Company as a current ratio of 8.08, with Debt / Equity ratio of 0.06%
Current Ratio8.08
Quick Ratio8.08
Debt to Market Cap<0.01
Net Debt to EBITDA3.19
Interest Coverage Ratio0.00
Taxes
In the past 12 months, NewAmsterdam Pharma Company has paid -1.00K in taxes.
Income Tax-1.00K
Effective Tax Rate<0.01
Enterprise Valuation
NewAmsterdam Pharma Company EV to EBITDA ratio is -6.85, with an EV/FCF ratio of -10.39.
EV to Sales36.29
EV to EBITDA-6.85
EV to Free Cash Flow-10.39
EV to Operating Cash Flow-10.43
Balance Sheet
NewAmsterdam Pharma Company has $834.19M in cash and marketable securities with $448.00K in debt, giving a net cash position of -$833.74M billion.
Cash & Marketable Securities$834.19M
Total Debt$448.00K
Net Cash-$833.74M
Net Cash Per Share-$7.43
Tangible Book Value Per Share$8.02
Margins
Gross margin is 99.85%, with operating margin of -386.91%, and net profit margin of -530.25%.
Gross Margin99.85%
Operating Margin-386.91%
Pretax Margin-530.25%
Net Profit Margin-530.25%
EBITDA Margin-530.00%
EBIT Margin-530.25%
Analyst Forecast
The average price target for NewAmsterdam Pharma Company is $42.43, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$42.43
Price Target Upside122.96% Upside
Analyst ConsensusStrong Buy
Analyst Count9
Revenue Growth Forecast―
EPS Growth Forecast―